Name	Max dose	Indication	PA Criteria	Units Dispensed	No of Rx	Units/Rx	Amount Paid	
Afinitor 5 mg			*1.Diagnosis of renal cell*					
(everolimus)	1/qd	Renal cell carcinoma	*carcinoma and*	420	15	26	$106,283.48	Yes
			2.Prior treatment with					
			Sutent (sunitinib) or					
			3.Prior treatment with					
			Nexavar (sorabfenib)					
			(Can utilize Auto PA)					
Afinitor 10 mg.	1 qd							
Caprelsa 100 mg.	1 qd	*Treatment of medullary thyroid*		604	24	25.17	$158,090.42	
(vandetanib)		*cancer that cannot be removed*						No
by surgery that has sp	*spread to c*	*to other parts of the body.*						
Caprelsa 300 mg.	1 qd							
Erivedge								
(vismodegib)	1 qd	*Treatment of adults with*						No
metastatic basal cell carcinoma		*(BCC) or locally advanced BCC*		30	1	30	$8,195.93	
that has recurred follc	*llowing surgery or who are not candidates*							
for surgery or radiation therapy.								
Gleevec 100 mg.								
imatinib)	3 qd	*Treatment of some forms of adult*		5820	63	92.35	$307,502.40	No
and pediatric chronic myelogenous leukemia (CML) and for the								
treatment of a rare form of cancer called gastrointestinal stromal								
tumor (GIST)								
Gleevec 400 mg.	2 qd			6690	219	30.55	$1,289,299.03	
Iressa 250 mg.								No
(gefitinab)	1 qd	*Monotherapy for the continued*						
treatment of locally advance or metastatic non-small cell lung								
cancer after failur of both planinum-based and docletaxol								
chemotherapies								
Jakafi 5 mg.	1 qd	*Treatment of patients with*						
(ruxolitinib)		*intermediate or high-risk*						No
jakafi 10 mg.	1 qd	*myelofibrosis (MF) including primary*						
jakafi 15 mg	2 qd	*MF, post polycythemia MF*						
Jakafi 20 mg.	2 qd	*and post-essential*						
Jakafi 25 mg	2 qd	*thrombocytopenia MF*						
Nexavar 200 mg.	4 qd	*Treatment of unresectable*		1080	11	96.18	$76,618.34	No
(sorafenib)		*hepatocarcinoma or advanced*						

		renal cell carcinoma						
Sprycel 20 mg.	2 qd	*Treatment of newly diagnosed*						
Philadelphia-chromosome postive chronic myeloid leukemia								Yes
(Ph+CML) in chronic phase. Treatment of adults with chronic								
accelerated or myeloid leukemia (CML) with rsistance or								
intolerance to prior therapy including imatinib (gleevec)								
Treatment of adults with Philadelphia chromosome-positive								
acute lymphoblastic leukemia wit resistance.								
Sprycel 50 mg.	**1 qd**			1450	25	58	$198,753.19	
Sprycel 70 mg.	**1 qd**			660	12	55	$90,260.18	
Sprycel 80 mg.	**1 qd**							
Sprycel 100 mg.	**1 qd**			920	31	29.68	252,533.65	
Sprycel 140 mg.	**1 qd**							
Sutent 12.5 mg.	**1 qd**	*Treatment of advanced renal cell*		420	15	28	$38,334.14	Yes
carcinoma, treatment of gastrointestinal stromal tumor (GIST)								
after disease progression on or intolerance to imanitib mesylate								
and for the treatment of progressive, well-differentiated								
pancreatic neuroendocrine tumors in patients with unresectable								
locally advanced or metastatic disease.								
Sutent 25 mg.	1 qd			322	12	26.83	$56,816.33	
Sutent 50 mg.	1 qd			350	14	25	$115,958.06	
Tarceva 25 mg.	3 qd							
(eriotinib)								
Tarceva 100 mg.	1 qd	*Maintenance treatment of patients*		330	11	30	$47,526.92	
locally advanced or metastatic		*non-small cell lung cancer (NSCLC)*						
whose disease has not after four		*cycles of platinum-based first line*						
chemotherapy, treatment of pati		*atients with locally advanced or*						
metastatic non-small cell lung cancer after failur of at least								
one prior chemotherapy regimen, and in combination with								
gemcitabine is indicated for the first-line treatment of patients								
with locally advanced, unresectable or metastatic pancreatic								
cancer.				1500	50	30	$25,054,167	
Tarceva 150 mg.	1 qd							
Tasigna 150 mg.	4 qd			330	11	30	47528.92	No
(nilotinib)								
Tasigna 200 mg.	4 qd	*Treatment of adult patients with*						
newly diagnosed Philadelphia chromosome-positive chronic				3528	32	110.25	$245,326.88	

myeloid leukemia (Ph+CML)		*in chronic phasel Indicated for*						
Treatment of chronic phase and accelerated phase Ph+CML								
in adults resistant or intolerant to prior therapy with imatinib.								
Tykerb 250 mg.	*6 day*	*Indicated in combination with*		3350	30	111.67	$92,570.64	No
capecitabine for the treatment of patients with advanced or								
metastatic breast cancer whose tumors overexpress HER2 and								
received prior therapy including an anthracycline, a taxane								
and trastuzumab or tertozole for the treatment of post-								
menopausal women with hormone receptor postitive								
metastatic breast cancer that overexpressses the HER2 receptor								
for whom hormonal therapy is indicated.								
Votrient	4 day	*Advanced renal cell crcinoma*	*Diagnosis of advanced*	240	2	120		Yes
		(Can use Auto PA)	*renal cell carcinoma*				$11,660.02	
Temodar		*Adult patients with glioblastoma*						No
multiforme concomitantly with radiotherapy and then as maintenance								
refractory anaplastic astrocytoma patient who have experienced								
disease progression on a drug regime of nitrosurea and procarbazine								
Xalkori 200 mg.	2 qd			120	2	60	$19,526.62	No
(crizotinib)								
Xalkori 250 mg.	2 qd	*Treatment of patients with locally*		60	1	60	$9,763.31	
advanced or metastatic non-small cell lung cancer (NCSLC) that								
is anaplastic lymphome kinase (A		*(ALK)-positive as detected by an*						
FDA approved test.								
Zelboraf 240 mg.	6 qd	*Treatment for BRAF mutation-*						
(vemurapanib)		*positive metastatic melanoma*						No
Zytiga 250 mg.	4 qd	*Use in combination with prednisone*		1664	7	237.71	$72,390.22	
(abiraterone)								
for the treatment of patients with metastatic castration-resistant								No
prostate cancer who have received prior chemotherapy containing								
docetaxol.								
109 unique patients		**8/27/11-8/26/12**						